在欧洲儿童非霍奇金淋巴瘤学术联盟框架下，经过25年的研究与合作，改善了儿童和青少年非霍奇金淋巴瘤的预后。
Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma.
发表日期：2023 Mar
作者：
Auke Beishuizen, Karin Mellgren, Mara Andrés, Anne Auperin, Chris M Bacon, Simon Bomken, G A Amos Burke, Birgit Burkhardt, Laurence Brugieres, Alan K S Chiang, Christine Damm-Welk, Emanuele d'Amore, Keizo Horibe, Edita Kabickova, Tasneem Khanam, Udo Kontny, Wolfram Klapper, Laurence Lamant, Marie-Cecile Le Deley, Jan Loeffen, Elizabeth Macintyre, Georg Mann, Friederike Meyer-Wentrup, Ulf Michgehl, Veronique Minard-Colin, Lara Mussolin, Ilske Oschlies, Catherine Patte, Marta Pillon, Alfred Reiter, Charlotte Rigaud, Leila Roncery, Itziar Salaverria, Ingrid Simonitsch-Klupp, Anne Uyttebroeck, Jaime Verdu-Amoros, Denise Williams, Wilhelm Woessmann, Andrew Wotherspoon, Grazyna Wrobel, Martin Zimmermann, Andishe Attarbaschi, Suzanne D Turner,
来源：
Stem Cell Research & Therapy
摘要：
欧洲儿童非何杰金淋巴瘤联合小组(EICNHL)成立于25年前，旨在促进欧洲和全球范围的临床试验和研究合作。自成立以来，该联合小组取得了很大的进展，取得了重大的治疗成果。在本次回顾中，我们描述了儿童和年轻成人非何杰金淋巴瘤的不同诊断实体，并描述了每个实体的关键特征和EICNHL框架下的临床成果。此外，我们概述了生物病理学的进展，重点介绍了生物研究的作用以及它们如何塑造现有的治疗方法。最后，针对每个实体，我们描述了未来的目标、即将进行的临床试验，并突出需要我们继续关注的研究领域。 版权所有©2023 Elsevier Ltd.。
The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) was established 25 years ago with the goal to facilitate clinical trials and research collaborations in the field both within Europe and worldwide. Since its inception, much progress has been made whereby major improvements in outcomes have been achieved. In this Review, we describe the different diagnostic entities of non-Hodgkin lymphoma in children and young adults describing key features of each entity and outlining clinical achievements made in the context of the EICNHL framework. Furthermore, we provide an overview of advances in biopathology with an emphasis on the role of biological studies and how they have shaped available treatments. Finally, for each entity, we describe future goals, upcoming clinical trials, and highlight areas of research that require our focus going forward.Copyright © 2023 Elsevier Ltd. All rights reserved.